[PDF][PDF] “MIATA”—minimal information about T cell assays

S Janetzki, CM Britten, M Kalos, HI Levitsky… - Immunity, 2009 - cell.com
S Janetzki, CM Britten, M Kalos, HI Levitsky, HT Maecker, CJM Melief, LJ Old, P Romero…
Immunity, 2009cell.com
Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the
treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et
al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested
in patients with a variety of tumor types and chronic viral diseases. Often, the best way to
assess the clinical potential of these vaccines is to monitor the induced T cell response, and
yet there are currently no standards for reporting these results. This letter is an effort to …
Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.
cell.com